Abstract:Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by left ventricular hypertrophy that can lead to heart failure, arrhythmias, and sudden cardiac death. Despite extensive research, the molecular mechanisms underlying HCM are not fully understood, and effective treatments remain limited. By leveraging bioinformatics and experimental validation, this study aims to identify key genes and pathways involved in HCM, uncover novel drug candidates, and provide new insights into its pathogenesis and potential therapeutic strategies. Methods: Commonly upregulated and downregulated genes in hypertrophic cardiomyopathy (HCM) were identified using Gene Expression Omnibus (GEO) datasets, including three mRNA profiling datasets and one miRNA expression dataset. Enrichment analysis and hub-gene exploration were performed using interaction networks and consistent miRNA-mRNA matches. Potential drugs for HCM were screened. HCM cellular and animal models were established using isoproterenol. Key unstudied differentially expressed genes (DEGs) were validated. Animals were treated with novel potential drugs, and improvements in HCM were assessed via ultrasound metrics. Hematoxylin and eosin (H&E) staining was used to assess myocardial fibrosis. Immunohistochemistry was employed to detect DEGs in cellular experiments. Result: We discovered 145 key upregulated and 149 downregulated DEGs associated with HCM development, among which there are eight core upregulated and seven core downregulated genes. There are 30 upregulated and six downregulated miRNAs. Between the six downregulated miRNAs and 1291 matched miRNAs (against eight core upregulated DEGs), there is one common miRNA, miR-1469. Using the CTD database, drugs that impact the expression/abundance/methylation/metabolic process of core DEGs (after the exclusion of toxic drugs) included acetaminophen, propylthiouracil, methapyrilene, triptolide, tretinoin, etc. In the HCM cell model, only ATRNL1 and WNT9A were significantly increased. In the HCM animal model, propylthiouracil, miR-1469, and triptolide demonstrated varying degrees of therapeutic effects on HCM. Propylthiouracil, but not miR-1469 or triptolide, significantly inhibited the expression of ATRNL1 in the HCM model, and all three drugs suppressed WNT9A expression. Conclusion: We identified several novel genes in HCM development, among which ATRNL1 and WNT9A were validated by cell and animal models. A deficiency of hsa-miR-1469 may be a mechanism behind HCM development. Novel medications for HCM treatment include propylthiouracil and triptolide.

A novel strategy for key gene identification in hypertrophic cardiomyopathy based on cuproptosis and multiple WGCNA analyses

Identification of Underlying Hub Genes Associated with Hypertrophic Cardiomyopathy by Integrated Bioinformatics Analysis

Pgpm_a_314880 823..837

Identification of Key Modules and Hub Genes in Hypertrophic Cardiomyopathy Based on Integrative Weighted Gene Co-expression Network Analysis

Identification of Biomarkers Correlated with Hypertrophic Cardiomyopathy with Co-Expression Analysis.

Identification of cuproptosis-related genes and immune infiltration in dilated cardiomyopathy

Identification and validation of pyroptosis-related genes as potential biomarkers for hypertrophic cardiomyopathy: A comprehensive bioinformatics analysis

Integration of Transcriptomic Data Identifies Key Hallmark Genes in Hypertrophic Cardiomyopathy

Identification of potential blood biomarkers of coronary artery disease using a cuproptosis gene set

Identification of ATRNL1 and WNT9A as novel key genes and drug candidates in hypertrophic cardiomyopathy: integrative bioinformatics and experimental validation

Identification of important modules and biomarkers in diabetic cardiomyopathy based on WGCNA and LASSO analysis

Identification of novel key genes and signaling pathways in hypertrophic cardiomyopathy: evidence from bioinformatics and next generation sequencing data analysis

A personalized mRNA signature for predicting hypertrophic cardiomyopathy applying machine learning methods

Machine learning and experimental validation of novel biomarkers for hypertrophic cardiomyopathy and cancers

Machine learning‐driven diagnostic signature provides new insights in clinical management of hypertrophic cardiomyopathy

Novel Algorithm for Diagnosis of Arrhythmogenic Cardiomyopathy and Dilated Cardiomyopathy: Key Gene Expression Profiling Using Machine Learning

Transcriptomics data integration and analysis to uncover hallmark genes in hypertrophic cardiomyopathy

Screening and validating genes associated with cuproptosis in systemic lupus erythematosus by expression profiling combined with machine learning

Identification of Circulating Hub Long Noncoding RNAs Associated with Hypertrophic Cardiomyopathy Using Weighted Correlation Network Analysis

Identification of Potential Biomarkers for Coronary Artery Disease Based on Cuproptosis

Identification of Potential miRNA-mRNA Regulatory Network Contributing to Hypertrophic Cardiomyopathy (HCM)